Gene Therapy for proliferative vitreoretinopathy
US6869935B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 16, 1998 |
| Grant date | Mar 22, 2005 |
| Priority date | — |
| Expiry date | Oct 16, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating ocular disorders (such as, for example, proliferative vitreoretinopathy or PVR) associated with replicating ocular cells by transfecting replicating ocular cells in vivo with a polynucleotide encoding an agent which is capable of providing for the inhibition, prevention, or destruction of the growth of the replicating ocular cells upon expression of the agent. The agent may be a viral thymidine kinase, and the polynucleotide encoding the agent may be contained in a retroviral vector. Once the replicating ocular cells are transduced with the retroviral vector, the patient is given a chemotherapeutic or interaction agent, such as ganciclovir, which kills the transfected replicating ocular cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.